188 related articles for article (PubMed ID: 37072666)
1. Immunohistochemical and ultrastructural review of six cases previously diagnosed as null cell PitNETs.
Inoshita N; Yoshimoto T; Takazawa Y; Fukuhara N; Okada M; Nishioka H; Yamada S
Brain Tumor Pathol; 2023 Jul; 40(3):158-162. PubMed ID: 37072666
[TBL] [Abstract][Full Text] [Related]
2. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
3. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
4. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
Dottermusch M; Schüller U; Hagel C; Saeger W
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
[TBL] [Abstract][Full Text] [Related]
5. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
6. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
7. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
8. Follicular cells in pituitary neuroendocrine tumors.
Delfin L; Mete O; Asa SL
Hum Pathol; 2021 Aug; 114():1-8. PubMed ID: 33991528
[TBL] [Abstract][Full Text] [Related]
9. Pangenomic Classification of Pituitary Neuroendocrine Tumors.
Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G
Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967
[TBL] [Abstract][Full Text] [Related]
10. TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.
Yao H; Xie W; Dai Y; Liu Y; Gu W; Li J; Wu L; Xie J; Rui W; Ren B; Xue L; Cheng Y; Lin S; Li C; Tang H; Wang Y; Lou M; Zhang X; Hu R; Shang H; Huang J; Wu ZB
Neuro Oncol; 2022 Aug; 24(8):1286-1297. PubMed ID: 35218667
[TBL] [Abstract][Full Text] [Related]
11. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors.
Mete O; Asa SL
Endocr Pathol; 2020 Dec; 31(4):330-336. PubMed ID: 32813227
[TBL] [Abstract][Full Text] [Related]
12. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience.
Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E
Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981
[No Abstract] [Full Text] [Related]
13. Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours.
Øystese KAB; Casar-Borota O; Berg-Johnsen J; Berg JP; Bollerslev J
Endocrine; 2022 Jun; 77(1):151-159. PubMed ID: 35674926
[TBL] [Abstract][Full Text] [Related]
14. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology.
Doğukan FM; Karatay H; Yüzkan S; Burhan Ş; Erkan B; Yılmaz-Özgüven B
Arch Pathol Lab Med; 2024 Apr; ():. PubMed ID: 38649148
[TBL] [Abstract][Full Text] [Related]
16. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
Mete O; Kefeli M; Çalışkan S; Asa SL
Mod Pathol; 2019 Apr; 32(4):484-489. PubMed ID: 30390035
[TBL] [Abstract][Full Text] [Related]
17. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
Luo M; Tang R; Wang H
J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
[TBL] [Abstract][Full Text] [Related]
18. [Medical Therapies in Functioning Pituitary Neuroendocrine Tumors(PitNETs)].
Nagamine T; Fukuda I
No Shinkei Geka; 2023 Jul; 51(4):706-715. PubMed ID: 37491068
[TBL] [Abstract][Full Text] [Related]
19. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
[TBL] [Abstract][Full Text] [Related]
20. Aggressive nonfunctioning pituitary neuroendocrine tumors.
Portovedo S; Neto LV; Soares P; Carvalho DP; Takiya CM; Miranda-Alves L
Brain Tumor Pathol; 2022 Oct; 39(4):183-199. PubMed ID: 35725837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
